I-BRD9

SKU: orb1300400

Description

I-BRD9

Research Area

Epigenetics & Chromatin

Key Properties

• CAS Number: 1714146-59-4
• MW: 497.55
• Purity: 99.51% (May vary between batches)
• Formula: C₂₂H₂₂F₃N₃O₃S₂
• SMILES: CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1
• Target: Epigenetic Reader Domain
• Solubility: DMSO:30 mg/mL (60.3 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.01 mM)

Bioactivity

• Target IC50:
  BRD9:7.3 (pIC50)
• In Vitro:
  I-BRD9 is identified through structure-based design, leading to greater than 700-fold selectivity over the BET family and 200-fold over the highly homologous bromodomain-containing protein 7 (BRD7). I-BRD9 is used to identify genes regulated by BRD9 in Kasumi-1 cells involved in oncology and immune response pathways and to the best of our knowledge, represents the first selective tool compound available to elucidate the cellular phenotype of BRD9 bromodomain inhibition.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BRD9, cancer, bromodomain-containing protein 7(BRD7), bromodomain and extra terminal domain (BET), Inhibitor, I BRD9, IBRD9, I-BRD9, I-BRD-9, EpigeneticReaderDomain, Epigenetic Reader Domain, GSK602, GSK-602, GSK 602, inhibit, immune response, Kasumi-1 cells, probe

Compound Identifiers

PubChem CID

91668541